New antipsychotic ITI-007 put to the test in large schizophrenia trial

NCT ID NCT02469155

Completed Disease control Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. Participants received either ITI-007, a placebo, or an active comparator (risperidone) for 6 weeks. The main goal was to see if ITI-007 reduces schizophrenia symptoms better than placebo, as measured by a standard symptom scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ITI-007 (an experimental antipsychotic drug)
What this could lead to: If successful, ITI-007 could offer a new treatment option for schizophrenia with possibly fewer side effects than current drugs.
What could go wrong: This is a completed Phase 3 trial, but results may not show clear benefit over placebo or existing drugs. Side effects and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Clinical Site

Little Rock, Arkansas, United States
Clinical Site

Springdale, Arkansas, United States
Clinical Site

Culver City, California, United States
Clinical Site

Lemon Grove, California, United States
Clinical Site

Long Beach, California, United States
Clinical Site

San Diego, California, United States
Clinical Site

North Miami, Florida, United States
Clinical Site

Berlin, New Jersey, United States
Clinical Site

Marlton, New Jersey, United States
Clinical Site

Austin, Texas, United States
Clinical Site

Dallas, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.